Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil
AssigneeAGI Therapeutics Ltd.
InventorsJohn Kelly, John Devane
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using enriched (R)-verapamil, as well as compositions and formulations containing the same.
Claims29
A method for treating an abnormal increase in gastrointestinal motility comprising administering a therapeutically effective amount of enriched (R)-verapamil, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
A method for preventing an abnormal increase in gastrointestinal motility comprising administering a therapeutically effective amount of enriched (R)-verapamil, or a pharmaceutically acceptable salt thereof, to a subject in need of such administration.
A method for managing an abnormal increase in gastrointestinal motility comprising administering a therapeutically effective amount of enriched (R)-verapamil, or a pharmaceutically acceptable salt thereof, to a subject in need of such administration.
A method for reducing an abnormal increase in gastrointestinal motility comprising administering a therapeutically effective amount of enriched (R)-verapamil, or a pharmaceutically acceptable salt thereof, to a subject in need of such administration.
Dependencies are inferred from the claim text.